Biotechnology company GeoVax Labs will provide a comprehensive update on its Mpox vaccine program during the upcoming Emerging Growth Conference. Company Chairman and CEO David Dodd is scheduled to present detailed information about GEO-MVA, the organization's vaccine candidate targeting Mpox and smallpox, on February 19, 2025.
The live, interactive online event offers shareholders and investment professionals an opportunity to gain direct insights into GeoVax's infectious disease research and development strategies. During the 2:55 pm ET presentation, Dodd will likely discuss the current status of GEO-MVA's development, potential clinical applications, and the company's broader approach to addressing critical public health challenges.
This presentation comes at a critical time for infectious disease research, as global health organizations continue to monitor emerging viral threats. The GEO-MVA vaccine candidate represents a potential significant advancement in preventing Mpox and smallpox, two viral diseases with substantial public health implications.
Beyond the Mpox vaccine, GeoVax is simultaneously advancing multiple research initiatives. The company is actively developing a next-generation COVID-19 vaccine, GEO-CM04S1, which is currently undergoing multiple Phase 2 clinical trials. These trials explore the vaccine's potential for immunocompromised patients, as a booster for specific patient populations, and as a more robust alternative to existing mRNA vaccines.
In addition to infectious disease research, GeoVax is expanding its oncology portfolio. The company is evaluating Gedeptin®, a novel gene-directed therapy for solid tumors, with plans for a Phase 2 clinical trial focusing on recurrent head and neck cancers.
The conference presentation represents an important opportunity for GeoVax to communicate its scientific progress, research strategies, and potential contributions to addressing critical global health challenges. Investors and healthcare professionals will be closely monitoring the insights shared during Dodd's presentation to understand the company's current trajectory and potential future impact.
